Cytokines in Cancer Immunotherapy
Cytokines that control the immune response were shown to have efficacy in preclinical murine cancer models. Interferon (IFN)-α is approved for treatment of hairy cell leukemia, and interleukin (IL)-2 for the treatment of advanced melanoma and metastatic renal cancer. In addition, IL-12, IL-15, IL-21...
Uloženo v:
| Vydáno v: | Cold Spring Harbor perspectives in biology Ročník 10; číslo 12 |
|---|---|
| Hlavní autor: | |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.12.2018
|
| ISSN: | 1943-0264, 1943-0264 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Cytokines that control the immune response were shown to have efficacy in preclinical murine cancer models. Interferon (IFN)-α is approved for treatment of hairy cell leukemia, and interleukin (IL)-2 for the treatment of advanced melanoma and metastatic renal cancer. In addition, IL-12, IL-15, IL-21, and granulocyte macrophage colony-stimulating factor (GM-CSF) have been evaluated in clinical trials. However, the cytokines as monotherapy have not fulfilled their early promise because cytokines administered parenterally do not achieve sufficient concentrations in the tumor, are often associated with severe toxicities, and induce humoral or cellular checkpoints. To circumvent these impediments, cytokines are being investigated clinically in combination therapy with checkpoint inhibitors, anticancer monoclonal antibodies to increase the antibody-dependent cellular cytotoxicity (ADCC) of these antibodies, antibody cytokine fusion proteins, and anti-CD40 to facilitate tumor-specific immune responses. |
|---|---|
| AbstractList | Cytokines that control the immune response were shown to have efficacy in preclinical murine cancer models. Interferon (IFN)-α is approved for treatment of hairy cell leukemia, and interleukin (IL)-2 for the treatment of advanced melanoma and metastatic renal cancer. In addition, IL-12, IL-15, IL-21, and granulocyte macrophage colony-stimulating factor (GM-CSF) have been evaluated in clinical trials. However, the cytokines as monotherapy have not fulfilled their early promise because cytokines administered parenterally do not achieve sufficient concentrations in the tumor, are often associated with severe toxicities, and induce humoral or cellular checkpoints. To circumvent these impediments, cytokines are being investigated clinically in combination therapy with checkpoint inhibitors, anticancer monoclonal antibodies to increase the antibody-dependent cellular cytotoxicity (ADCC) of these antibodies, antibody cytokine fusion proteins, and anti-CD40 to facilitate tumor-specific immune responses.Cytokines that control the immune response were shown to have efficacy in preclinical murine cancer models. Interferon (IFN)-α is approved for treatment of hairy cell leukemia, and interleukin (IL)-2 for the treatment of advanced melanoma and metastatic renal cancer. In addition, IL-12, IL-15, IL-21, and granulocyte macrophage colony-stimulating factor (GM-CSF) have been evaluated in clinical trials. However, the cytokines as monotherapy have not fulfilled their early promise because cytokines administered parenterally do not achieve sufficient concentrations in the tumor, are often associated with severe toxicities, and induce humoral or cellular checkpoints. To circumvent these impediments, cytokines are being investigated clinically in combination therapy with checkpoint inhibitors, anticancer monoclonal antibodies to increase the antibody-dependent cellular cytotoxicity (ADCC) of these antibodies, antibody cytokine fusion proteins, and anti-CD40 to facilitate tumor-specific immune responses. Cytokines that control the immune response were shown to have efficacy in preclinical murine cancer models. Interferon (IFN)-α is approved for treatment of hairy cell leukemia, and interleukin (IL)-2 for the treatment of advanced melanoma and metastatic renal cancer. In addition, IL-12, IL-15, IL-21, and granulocyte macrophage colony-stimulating factor (GM-CSF) have been evaluated in clinical trials. However, the cytokines as monotherapy have not fulfilled their early promise because cytokines administered parenterally do not achieve sufficient concentrations in the tumor, are often associated with severe toxicities, and induce humoral or cellular checkpoints. To circumvent these impediments, cytokines are being investigated clinically in combination therapy with checkpoint inhibitors, anticancer monoclonal antibodies to increase the antibody-dependent cellular cytotoxicity (ADCC) of these antibodies, antibody cytokine fusion proteins, and anti-CD40 to facilitate tumor-specific immune responses. |
| Author | Waldmann, Thomas A |
| Author_xml | – sequence: 1 givenname: Thomas A surname: Waldmann fullname: Waldmann, Thomas A organization: Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Clinical Center, Bethesda, Maryland 20892-1374 |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29101107$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj01LxDAYhIOsuB_6CwSpNy9d33w0TY5SVl1Y8KLnkiZv2Gqb1qY97L-34AqeZhgehpk1WYQuICG3FLaUAn208djjEHu049YAUyJnF2RFteApMCkW__ySrGP8BJBSK3lFlkzPBRTyFbkvTmP3VQeMSR2SwgSLQ7Jv2yl04xEH05-uyaU3TcSbs27Ix_PuvXhND28v--LpkFrB-ZhmXufcIuMWfO6dkMil48xIpRS1jAnmKkN5JnkGHrJ5sFOQO1kp8HMm2YY8_Pb2Q_c9YRzLto4Wm8YE7KZYUi1BM60gm9G7MzpVLbqyH-rWDKfy7xb7AVf-UTI |
| CitedBy_id | crossref_primary_10_1093_intimm_dxaa037 crossref_primary_10_1038_s41392_024_01934_w crossref_primary_10_3390_cancers12123586 crossref_primary_10_1093_abt_tbab014 crossref_primary_10_3390_ijms232214313 crossref_primary_10_4103_0973_029X_325257 crossref_primary_10_1038_s41587_022_01510_z crossref_primary_10_1155_2020_7142375 crossref_primary_10_1016_j_cytogfr_2024_03_002 crossref_primary_10_1186_s12943_021_01489_2 crossref_primary_10_3390_cancers16193250 crossref_primary_10_3390_jcm12093127 crossref_primary_10_1016_j_intimp_2021_108307 crossref_primary_10_3892_mco_2025_2872 crossref_primary_10_1158_2326_6066_CIR_24_1192 crossref_primary_10_3390_ijms25021195 crossref_primary_10_3892_ol_2025_15170 crossref_primary_10_1016_j_ygeno_2021_11_037 crossref_primary_10_1097_MD_0000000000037030 crossref_primary_10_1186_s40164_024_00561_z crossref_primary_10_1007_s00262_023_03453_z crossref_primary_10_1016_j_canlet_2021_10_034 crossref_primary_10_1016_j_brachy_2020_10_012 crossref_primary_10_1038_s41598_022_25059_8 crossref_primary_10_1007_s11033_022_07525_8 crossref_primary_10_1002_mco2_70346 crossref_primary_10_1186_s12951_021_00861_0 crossref_primary_10_1172_JCI129338 crossref_primary_10_3389_fimmu_2021_765101 crossref_primary_10_1182_bloodadvances_2018028332 crossref_primary_10_3390_cancers15041324 crossref_primary_10_3390_pharmaceutics15061625 crossref_primary_10_1136_jitc_2024_010580 crossref_primary_10_1186_s13045_019_0746_1 crossref_primary_10_1016_j_cytogfr_2023_09_005 crossref_primary_10_1084_jem_20191062 crossref_primary_10_1016_j_prp_2023_154528 crossref_primary_10_3389_fimmu_2023_1218082 crossref_primary_10_1038_s41423_020_0488_6 crossref_primary_10_1016_j_semcancer_2022_01_008 crossref_primary_10_3389_fimmu_2024_1446532 crossref_primary_10_32604_or_2023_027942 crossref_primary_10_3390_vaccines13010069 crossref_primary_10_1038_s41417_020_0179_6 crossref_primary_10_2174_0115733947290954240402060311 crossref_primary_10_3390_pharmaceutics13040525 crossref_primary_10_1007_s00262_024_03723_4 crossref_primary_10_1177_15330338221150555 crossref_primary_10_3390_ijms25031406 crossref_primary_10_1186_s12943_024_02183_9 crossref_primary_10_3390_pharmaceutics13040520 crossref_primary_10_1002_adma_202313188 crossref_primary_10_1039_D1NR05512G crossref_primary_10_1002_jcp_29491 crossref_primary_10_1186_s43556_025_00299_y crossref_primary_10_1155_2021_7855808 crossref_primary_10_1016_j_humimm_2023_08_145 crossref_primary_10_1016_j_biopha_2022_113903 crossref_primary_10_34133_bmr_0178 crossref_primary_10_2174_1381612825666190708214240 crossref_primary_10_3390_cancers13030373 crossref_primary_10_1016_j_heliyon_2023_e23919 crossref_primary_10_1016_j_omto_2021_01_011 crossref_primary_10_1002_anie_202212866 crossref_primary_10_3390_ijms24076477 crossref_primary_10_1016_j_cytogfr_2020_11_003 crossref_primary_10_3390_nano10071274 crossref_primary_10_1186_s13045_024_01528_7 crossref_primary_10_3390_cancers12123496 crossref_primary_10_1002_advs_202207074 crossref_primary_10_1038_s41392_021_00729_7 crossref_primary_10_1016_j_diii_2020_02_004 crossref_primary_10_1002_cac2_12539 crossref_primary_10_1002_adtp_202000147 crossref_primary_10_1038_s41586_020_2422_6 crossref_primary_10_1080_17425247_2023_2208344 crossref_primary_10_1136_jitc_2020_000973 crossref_primary_10_3389_fimmu_2025_1480496 crossref_primary_10_1016_j_smim_2019_101307 crossref_primary_10_1002_adhm_202001680 crossref_primary_10_1002_chem_202302948 crossref_primary_10_1016_j_omton_2025_201022 crossref_primary_10_3389_fonc_2022_919072 crossref_primary_10_3390_cancers13040719 crossref_primary_10_1016_j_jconrel_2022_03_021 crossref_primary_10_1016_j_csbj_2022_08_050 crossref_primary_10_1016_j_hbpd_2021_06_010 crossref_primary_10_1016_j_intimp_2022_108580 crossref_primary_10_3390_ijms20040840 crossref_primary_10_1073_pnas_2318687121 crossref_primary_10_1016_j_phrs_2020_104691 crossref_primary_10_1016_j_addr_2021_113899 crossref_primary_10_3389_fcell_2023_1191774 crossref_primary_10_1038_s41401_024_01355_z crossref_primary_10_1158_0008_5472_CAN_19_2948 crossref_primary_10_1038_s41392_024_01868_3 crossref_primary_10_1016_j_addr_2021_113896 crossref_primary_10_1016_j_livres_2025_05_003 crossref_primary_10_3389_fimmu_2019_01805 crossref_primary_10_1016_j_cytogfr_2020_06_005 crossref_primary_10_1186_s12885_022_09633_x crossref_primary_10_3389_fimmu_2023_1130442 crossref_primary_10_3389_fimmu_2022_950079 crossref_primary_10_1186_s40425_018_0334_x crossref_primary_10_1016_j_beha_2025_101615 crossref_primary_10_1186_s12967_025_06403_8 crossref_primary_10_3390_antib9020017 crossref_primary_10_1002_prp2_778 crossref_primary_10_3390_ijms241411695 crossref_primary_10_1016_j_imbio_2024_152838 crossref_primary_10_1021_acs_bioconjchem_5c00182 crossref_primary_10_1002_wnan_1752 crossref_primary_10_1016_j_apsb_2024_07_011 crossref_primary_10_1016_j_prp_2024_155284 crossref_primary_10_1016_j_ymthe_2022_08_016 crossref_primary_10_1080_10428194_2023_2218508 crossref_primary_10_3389_fonc_2019_01073 crossref_primary_10_1186_s12967_025_06508_0 crossref_primary_10_1038_s41434_021_00256_8 crossref_primary_10_3389_fimmu_2025_1645371 crossref_primary_10_1016_j_ymthe_2021_12_002 crossref_primary_10_3389_fimmu_2024_1433185 crossref_primary_10_3390_molecules24183261 crossref_primary_10_3390_cancers17050880 crossref_primary_10_3390_toxins12040241 crossref_primary_10_1016_j_cyto_2025_156888 crossref_primary_10_1038_s42003_022_04403_8 crossref_primary_10_3389_fmed_2021_721174 crossref_primary_10_1016_j_biotechadv_2025_108592 crossref_primary_10_1016_j_semradonc_2019_12_008 crossref_primary_10_3390_cancers15082323 crossref_primary_10_1002_ajh_27471 crossref_primary_10_1186_s40164_025_00639_2 crossref_primary_10_1007_s10549_021_06405_2 crossref_primary_10_1186_s11658_024_00591_9 crossref_primary_10_3389_fimmu_2024_1429912 crossref_primary_10_1002_advs_202201734 crossref_primary_10_1016_j_seminoncol_2025_152345 crossref_primary_10_1016_j_bioactmat_2021_03_015 crossref_primary_10_1016_j_cyto_2022_155916 crossref_primary_10_3389_fonc_2025_1594621 crossref_primary_10_1038_s41587_024_02418_6 crossref_primary_10_3389_fimmu_2022_1023908 crossref_primary_10_1007_s10620_024_08774_2 crossref_primary_10_1186_s12967_024_05552_6 crossref_primary_10_3390_pr10010016 crossref_primary_10_1155_2021_4836292 crossref_primary_10_3390_jcm10143058 crossref_primary_10_1007_s00894_023_05690_6 crossref_primary_10_1089_jir_2024_0099 crossref_primary_10_3389_fimmu_2020_621225 crossref_primary_10_3389_fonc_2021_726701 crossref_primary_10_1158_2326_6066_CIR_21_0224 crossref_primary_10_3389_fmolb_2023_1190669 crossref_primary_10_1007_s12672_024_01638_1 crossref_primary_10_1039_D0MH00755B crossref_primary_10_1016_j_ijrobp_2020_04_023 crossref_primary_10_1016_j_nwnano_2025_100147 crossref_primary_10_3389_fimmu_2025_1623137 crossref_primary_10_3389_fphar_2022_928369 crossref_primary_10_1186_s12885_023_11603_w crossref_primary_10_1038_s41392_021_00868_x crossref_primary_10_1186_s12959_025_00719_7 crossref_primary_10_3390_ijms231810692 crossref_primary_10_3390_cancers15020342 crossref_primary_10_3389_fimmu_2022_1011264 crossref_primary_10_1016_j_biomaterials_2019_119265 crossref_primary_10_1038_s41571_021_00588_9 crossref_primary_10_1186_s13045_025_01664_8 crossref_primary_10_1002_aac2_70000 crossref_primary_10_1080_19420862_2023_2245111 crossref_primary_10_3389_fimmu_2020_00927 crossref_primary_10_3390_biology13030153 crossref_primary_10_1016_j_critrevonc_2024_104437 crossref_primary_10_3389_fgene_2024_1458047 crossref_primary_10_3389_fgene_2022_972212 crossref_primary_10_1186_s40364_021_00313_9 crossref_primary_10_3390_ijms25010211 crossref_primary_10_1038_s41571_023_00830_6 crossref_primary_10_1038_s41434_024_00497_3 crossref_primary_10_3748_wjg_v29_i6_1054 crossref_primary_10_3389_fimmu_2022_890166 crossref_primary_10_3389_fimmu_2023_1242911 crossref_primary_10_1016_j_jconrel_2020_06_029 crossref_primary_10_1038_s41392_022_00951_x crossref_primary_10_1002_mabi_202300275 crossref_primary_10_1002_EXP_20220170 crossref_primary_10_1016_j_ctarc_2025_101005 crossref_primary_10_1080_17460441_2021_1850689 crossref_primary_10_1007_s40495_019_00193_6 crossref_primary_10_1016_j_immuni_2019_03_028 crossref_primary_10_1136_jim_2021_002205 crossref_primary_10_3390_biomedicines13081908 crossref_primary_10_3389_fcell_2020_00210 crossref_primary_10_1007_s13206_019_3108_8 crossref_primary_10_1007_s11307_019_01393_8 crossref_primary_10_1038_s41568_021_00363_z crossref_primary_10_1186_s12943_024_02214_5 crossref_primary_10_1186_s12934_021_01605_3 crossref_primary_10_1186_s12935_022_02626_7 crossref_primary_10_1016_j_ymthe_2023_07_007 crossref_primary_10_1080_17460441_2021_1978972 crossref_primary_10_1016_j_jconrel_2019_09_011 crossref_primary_10_3389_fimmu_2024_1362775 crossref_primary_10_1186_s12951_025_03425_8 crossref_primary_10_1038_s41590_024_01956_0 crossref_primary_10_1136_jitc_2024_009716 crossref_primary_10_1159_000530161 crossref_primary_10_1002_mco2_68 crossref_primary_10_29219_fnr_v68_10545 crossref_primary_10_1039_D5TB01024A crossref_primary_10_3390_molecules26051220 crossref_primary_10_3389_fonc_2022_779786 crossref_primary_10_1155_2018_8321302 crossref_primary_10_3389_fphar_2023_1184703 crossref_primary_10_1016_j_molimm_2024_11_009 crossref_primary_10_3389_fimmu_2024_1430301 crossref_primary_10_1016_j_prp_2025_155928 crossref_primary_10_1136_gutjnl_2023_329650 crossref_primary_10_1186_s41231_023_00144_w crossref_primary_10_3390_cancers15143739 crossref_primary_10_3390_cancers12123653 crossref_primary_10_1016_j_jconrel_2024_09_041 crossref_primary_10_1186_s13045_020_00893_3 crossref_primary_10_3389_fonc_2021_688489 crossref_primary_10_1002_ijc_34602 crossref_primary_10_1002_btm2_10465 crossref_primary_10_3233_BD_220013 crossref_primary_10_3389_fonc_2019_00367 crossref_primary_10_1016_j_cyto_2022_155948 crossref_primary_10_1136_jitc_2025_012165 crossref_primary_10_1155_2020_2549763 crossref_primary_10_1002_smtd_202501401 crossref_primary_10_1136_jitc_2019_000493 crossref_primary_10_3389_fimmu_2023_1326927 crossref_primary_10_3389_fonc_2022_900985 crossref_primary_10_1186_s12967_024_05251_2 crossref_primary_10_3389_fimmu_2023_1175513 crossref_primary_10_7554_eLife_62927 crossref_primary_10_1002_advs_202505785 crossref_primary_10_3389_fcell_2020_00402 crossref_primary_10_3390_cimb47070537 crossref_primary_10_1158_2326_6066_CIR_21_0831 crossref_primary_10_1158_2326_6066_CIR_21_0952 crossref_primary_10_1016_j_jgg_2021_08_004 crossref_primary_10_1093_jnci_djae165 crossref_primary_10_1016_j_biopha_2021_112558 crossref_primary_10_3892_ijmm_2023_5336 crossref_primary_10_2147_IJN_S455213 crossref_primary_10_1080_2162402X_2021_1952539 crossref_primary_10_3389_fimmu_2022_872010 crossref_primary_10_1016_j_critrevonc_2025_104763 crossref_primary_10_1186_s12865_023_00553_4 crossref_primary_10_1111_epi_18261 crossref_primary_10_3390_cancers17091407 crossref_primary_10_1007_s42452_023_05593_4 crossref_primary_10_1007_s00018_021_03842_6 crossref_primary_10_3389_fimmu_2022_859177 crossref_primary_10_3389_fimmu_2021_620494 crossref_primary_10_3390_cells11030579 crossref_primary_10_1016_j_nantod_2024_102331 crossref_primary_10_1038_s41392_024_02050_5 crossref_primary_10_1016_j_bioactmat_2023_08_022 crossref_primary_10_1016_j_apsb_2020_12_018 crossref_primary_10_1097_CJI_0000000000000478 crossref_primary_10_1038_s44222_023_00148_z crossref_primary_10_1016_j_isci_2023_106523 crossref_primary_10_1186_s13045_020_00890_6 crossref_primary_10_1002_mco2_70387 crossref_primary_10_1016_j_jep_2019_111980 crossref_primary_10_1038_s12276_024_01353_5 crossref_primary_10_3389_fimmu_2022_884592 crossref_primary_10_3390_biom14091057 crossref_primary_10_3390_ijms22157802 crossref_primary_10_1038_s41586_025_09212_7 crossref_primary_10_1016_j_biopha_2024_116808 crossref_primary_10_1158_2326_6066_CIR_22_0705 crossref_primary_10_1002_ange_202212866 crossref_primary_10_1016_j_prp_2023_154846 crossref_primary_10_1007_s12032_025_02787_1 crossref_primary_10_1038_s41591_023_02284_w crossref_primary_10_1002_ijc_34060 crossref_primary_10_3389_fimmu_2023_1188277 crossref_primary_10_3390_diagnostics12123128 crossref_primary_10_1016_j_apsb_2024_09_009 crossref_primary_10_3390_cancers15102721 crossref_primary_10_1016_j_tcb_2023_04_001 crossref_primary_10_1002_adma_202409522 crossref_primary_10_31083_j_fbl2901013 crossref_primary_10_1016_j_eurpolymj_2022_111471 crossref_primary_10_3892_mmr_2024_13283 crossref_primary_10_1002_btm2_10417 crossref_primary_10_3390_ijms21218000 crossref_primary_10_1016_j_ejpb_2025_114789 crossref_primary_10_1111_imr_12920 crossref_primary_10_3389_fimmu_2025_1653829 crossref_primary_10_1182_blood_2021014495 crossref_primary_10_3390_cells9030564 crossref_primary_10_1038_s41587_025_02592_1 crossref_primary_10_1186_s12951_021_00975_5 crossref_primary_10_1038_s41416_018_0328_y crossref_primary_10_1080_15384047_2024_2376410 crossref_primary_10_1080_14789450_2024_2428332 crossref_primary_10_1007_s12094_020_02392_w crossref_primary_10_1093_pcmedi_pbae017 crossref_primary_10_1016_j_critrevonc_2024_104588 crossref_primary_10_3390_ijms25084170 crossref_primary_10_3389_fimmu_2022_985326 crossref_primary_10_3390_ijms19041246 crossref_primary_10_1007_s10238_018_0521_6 crossref_primary_10_3389_fimmu_2023_1202725 crossref_primary_10_3390_pharmaceutics17030383 crossref_primary_10_1136_jitc_2022_004493 crossref_primary_10_3390_pharmaceutics15020377 crossref_primary_10_31083_j_fbl2708240 crossref_primary_10_3390_cancers12103072 |
| ContentType | Journal Article |
| Copyright | Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved. |
| Copyright_xml | – notice: Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved. |
| DBID | NPM 7X8 |
| DOI | 10.1101/cshperspect.a028472 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1943-0264 |
| ExternalDocumentID | 29101107 |
| Genre | Journal Article Research Support, N.I.H., Intramural Review |
| GroupedDBID | --- 39C 53G 5VS 6J9 ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW DIK DU5 E3Z EBS EJD F5P GX1 H13 HYE KQ8 NPM OK1 RCX RHI RPM TR2 7X8 ACLKE |
| ID | FETCH-LOGICAL-c433t-5f973ce23c0f7fd46e36d32a68881c2242dba1356350f05a02d807d6b80f63562 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 378 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000451944700007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1943-0264 |
| IngestDate | Wed Oct 01 13:44:26 EDT 2025 Thu Apr 03 07:05:02 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| License | Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c433t-5f973ce23c0f7fd46e36d32a68881c2242dba1356350f05a02d807d6b80f63562 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | http://cshperspectives.cshlp.org/content/10/12/a028472.full.pdf |
| PMID | 29101107 |
| PQID | 1960929805 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1960929805 pubmed_primary_29101107 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-12-01 |
| PublicationDateYYYYMMDD | 2018-12-01 |
| PublicationDate_xml | – month: 12 year: 2018 text: 2018-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cold Spring Harbor perspectives in biology |
| PublicationTitleAlternate | Cold Spring Harb Perspect Biol |
| PublicationYear | 2018 |
| SSID | ssj0066986 |
| Score | 2.667567 |
| SecondaryResourceType | review_article |
| Snippet | Cytokines that control the immune response were shown to have efficacy in preclinical murine cancer models. Interferon (IFN)-α is approved for treatment of... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| Title | Cytokines in Cancer Immunotherapy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29101107 https://www.proquest.com/docview/1960929805 |
| Volume | 10 |
| WOSCitedRecordID | wos000451944700007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB7UKnjx_agvUvC6dpPdbJKTSLEoaOlBobew2QeKkNSmCv33ziZbPQmCl9wSMtnJ7Df7zXwDcIlxN8kUt0RIZQnnVBIZ0pTEoZRhphGA20Yy_yEZjdLJJBv7A7fal1UuY2ITqHWl3Bl5P3TSaFGW0vh6-k7c1CjHrvoRGqvQYQhlnFcnk28WQYismfSIebrjKgX3qkPohX1Vv0x9N-OVpC5GR79jzGavGW7_9y13YMujzOCmdYtdWDHlHmy0cycX-9AbLObVmyt4D17LYOAWfhbcu04R34-1OIDn4e3T4I74WQlEccbmJLZZwpSJmKI2sZoLw4RmkRSY4YYK9-lIFzJkMeILammMJuuUJloUKbVOoi46hLWyKs0xBLRggpvCSnwUZ45XSww3TCmteSZj1YXe0vYcfdERDLI01Ued_1jfhaP2A-bTVjQjjxCXuFzz5A93n8Im4pK0rRo5g47FP9Gcw7r6nL_Ws4tmkfE6Gj9-ARUKsQo |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cytokines+in+Cancer+Immunotherapy&rft.jtitle=Cold+Spring+Harbor+perspectives+in+biology&rft.au=Waldmann%2C+Thomas+A&rft.date=2018-12-01&rft.eissn=1943-0264&rft.volume=10&rft.issue=12&rft_id=info:doi/10.1101%2Fcshperspect.a028472&rft_id=info%3Apmid%2F29101107&rft_id=info%3Apmid%2F29101107&rft.externalDocID=29101107 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1943-0264&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1943-0264&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1943-0264&client=summon |